港股异动 | 百济神州(06160)午前涨近3% 多家创新药企中季报迎喜公司BTK药物在美市占率不断扩大

智通财经08-21

智通财经APP获悉，百济神州(06160)午前涨近3%，截至发稿，涨2.82%，报120.5港元，成交额9003.17万港元。消息面上，近日，多家创新药上市公司披露中报，营收和利润均实现较高增长，其背后主要受益于主营药品快速放量带动高增长，尤其是有的企业在海外市场取得重大突破，单是美国市场销售额就已经接近60亿元。汇丰研究发布研报指出，百济神州BTK抑制剂产品海外销售进展良好，第二季BTK销售额...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2461867038?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-21 11:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2461867038","market":"us","top_or_hot":-1,"title":"港股异动 | 百济神州(06160)午前涨近3% 多家创新药企中季报迎喜 公司BTK药物在美市占率不断扩大","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，百济神州(06160)午前涨近3%，截至发稿，涨2.82%，报120.5港元，成交额9003.17万港元。消息面上，近日，多家创新药上市公司披露中报，营收和利润均实现较高增长，其背后主要受益于主营药品快速放量带动高增长，尤其是有的企业在海外市场取得重大突破，单是美国市场销售额就已经接近60亿元。汇丰研究发布研报指出，百济神州BTK抑制剂产品海外销售进展良好，第二季BTK销售额...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1167479.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 百济神州(06160)午前涨近3% 多家创新药企中季报迎喜 公司BTK药物在美市占率不断扩大</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 百济神州(06160)午前涨近3% 多家创新药企中季报迎喜 公司BTK药物在美市占率不断扩大\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-21 11:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1167479.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，百济神州(06160)午前涨近3%，截至发稿，涨2.82%，报120.5港元，成交额9003.17万港元。消息面上，近日，多家创新药上市公司披露中报，营收和利润均实现较高增长，其背后主要受益于主营药品快速放量带动高增长，尤其是有的企业在海外市场取得重大突破，单是美国市场销售额就已经接近60亿元。汇丰研究发布研报指出，百济神州BTK抑制剂产品海外销售进展良好，第二季BTK销售额...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1167479.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159992","symbol_name":"创新药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1167479.html","article_id":"2461867038","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2461867038","pubTimestamp":1724211792,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，百济神州午前涨近3%，截至发稿，涨2.82%，报120.5港元，成交额9003.17万港元。消息面上，近日，多家创新药上市公司披露中报，营收和利润均实现较高增长，其背后主要受益于主营药品快速放量带动高增长，尤其是有的企业在海外市场取得重大突破，单是美国市场销售额就已经接近60亿元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","688235":"百济神州","BK4516":"特朗普概念","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK1500":"做空集合股","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BGNE":"百济神州","BK4007":"制药","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK1588":"回港中概股","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","MRK":"默沙东","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","BK4588":"碎股","BK4526":"热门中概股","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","06160":"百济神州","BK4505":"高瓴资本持仓","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4504":"桥水持仓","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4548":"巴美列捷福持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","06978":"永泰生物-B","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC"},"translate_title":"Changes in Hong Kong stocks BeiGene (06160) rose nearly 3% before noon. Many innovative pharmaceutical companies welcomed their mid-quarter reports. The company's BTK drug continues to expand its market share in the United States","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"688235":1,"06978":1,"MRK":1,"BT":1,"BGNE":1,"06160":1},"content_text":"智通财经APP获悉，百济神州(06160)午前涨近3%，截至发稿，涨2.82%，报120.5港元，成交额9003.17万港元。消息面上，近日，多家创新药上市公司披露中报，营收和利润均实现较高增长，其背后主要受益于主营药品快速放量带动高增长，尤其是有的企业在海外市场取得重大突破，单是美国市场销售额就已经接近60亿元。汇丰研究发布研报指出，百济神州BTK抑制剂产品海外销售进展良好，第二季BTK销售额按年增长107%至6.37亿美元，超出市场预期，当中核心产品“泽布替尼”在美国的销售额达到4.79亿美元，按年增长114%，按季亦增长37%，相信主要来自于适应症增加带动美国市场占有率提升。该行续指，公司估值具有吸引力，因为其BTK产品市占率正不断提升，由于治疗时间较长，长远为销售高峰带来动力，预期下一个潜在增长动力将是BCL-2抑制剂及抗体偶联药物(ADC)的发展。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461867038"}

港股异动 | 百济神州(06160)午前涨近3% 多家创新药企中季报迎喜 公司BTK药物在美市占率不断扩大

精彩评论

港股异动 | 百济神州(06160)午前涨近3% 多家创新药企中季报迎喜公司BTK药物在美市占率不断扩大